Integra LifeSciences (NASDAQ:IART) Stock Rating Upgraded by StockNews.com

Integra LifeSciences (NASDAQ:IART) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued to investors on Thursday.

IART has been the topic of several other reports. JMP Securities reduced their price objective on Integra LifeSciences from $55.00 to $49.00 and set a “market outperform” rating on the stock in a report on Thursday, February 29th. Truist Financial cut their price target on Integra LifeSciences from $46.00 to $41.00 and set a “hold” rating on the stock in a research note on Friday, March 1st. Finally, Wells Fargo & Company raised shares of Integra LifeSciences from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $40.00 to $49.00 in a research note on Tuesday, December 5th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $45.00.

Integra LifeSciences Trading Up 1.8 %

NASDAQ IART traded up $0.62 on Thursday, hitting $35.45. 823,648 shares of the stock were exchanged, compared to its average volume of 653,868. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.18 and a current ratio of 3.45. Integra LifeSciences has a 52-week low of $33.24 and a 52-week high of $59.33. The firm has a market capitalization of $2.79 billion, a P/E ratio of 42.71, a P/E/G ratio of 1.02 and a beta of 1.13. The stock has a fifty day moving average price of $39.49 and a two-hundred day moving average price of $39.70.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Wednesday, February 28th. The life sciences company reported $0.89 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.90 by ($0.01). The firm had revenue of $397.00 million during the quarter, compared to the consensus estimate of $399.30 million. Integra LifeSciences had a return on equity of 15.19% and a net margin of 4.39%. Integra LifeSciences’s revenue was down .3% compared to the same quarter last year. During the same quarter last year, the business posted $0.94 EPS. Research analysts forecast that Integra LifeSciences will post 3.19 EPS for the current fiscal year.

Hedge Funds Weigh In On Integra LifeSciences

Several institutional investors and hedge funds have recently bought and sold shares of IART. Signaturefd LLC increased its holdings in shares of Integra LifeSciences by 248.5% during the fourth quarter. Signaturefd LLC now owns 582 shares of the life sciences company’s stock valued at $25,000 after acquiring an additional 415 shares in the last quarter. Hexagon Capital Partners LLC increased its stake in Integra LifeSciences by 123.3% during the 4th quarter. Hexagon Capital Partners LLC now owns 670 shares of the life sciences company’s stock valued at $29,000 after purchasing an additional 370 shares in the last quarter. Itau Unibanco Holding S.A. raised its holdings in shares of Integra LifeSciences by 469.5% in the second quarter. Itau Unibanco Holding S.A. now owns 746 shares of the life sciences company’s stock worth $31,000 after buying an additional 615 shares during the last quarter. Gladius Capital Management LP acquired a new stake in shares of Integra LifeSciences during the third quarter worth $48,000. Finally, Covestor Ltd grew its holdings in shares of Integra LifeSciences by 63.0% during the first quarter. Covestor Ltd now owns 1,558 shares of the life sciences company’s stock valued at $100,000 after buying an additional 602 shares during the last quarter. 84.78% of the stock is owned by hedge funds and other institutional investors.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.